New York, Jan. 13, 2014 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that NeoStem and PCT will present at five sessions at the Phacilitate Cell & Gene Therapy Forum 2014 in Washington DC.
Of particular note is the January 29 Breakfast Workshop hosted by PCT which will focus on PCT's Development by Design ("DbD") concept, aimed at helping PCT's clients methodically identify and address quality, cost, scale, and sustainability goals that are both challenging and critical for commercial-scale manufacture of cell therapy products.
"PCT's DbD methodology is designed to inform and accelerate the use of engineering principles and innovative solutions such as automation, integration, and closed system design, to provide a manufacturing process that will meet these commercial goals," said Brian Hampson, Senior Director, Engineering & Innovation services at PCT, and leader of the Workshop. "DbD provides a systems approach to guide strategy for manufacturing development and can be applied across the full range of cell-based therapeutic products."
The Company's other presentations range in topic from business to product characterization assays and a case study on CD34+ bone marrow stem cells in interventional cardiology.
"We are proud to showcase the depth and breadth of our resources at Phacilitate," Dr. Robert A. Preti, Chief Scientific Officer of PCT and NeoStem and President of PCT, "and demonstrate how PCT can provide solutions that help our clients achieve their cell therapy development and commercialization goals."
Phacilitate Cell & Gene Therapy Forum 2014
January 27-29, 2014
Grand Hyatt, Washington, DC
Monday, January 27, 2014
Session #1: Cell & Gene Therapy Business
- Time: 9:00 AM EST
- Speaker: Robert A. Preti, PhD, Chief Scientific Officer and President of PCT
Session #2: Product characterization assays – what are they good for?
- Time: 12:25 PM EST
- Speaker:Timothy Fong, PhD, MBA, Vice President, Technology &Product Development, PCT
Tuesday, January 28, 2014
Session: Challenges and future directions for commercial scale manufacturing
- Time: 3:00 PM EST
- Speaker: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT
Wednesday, January 29, 2014
Session #1: Development by Design (DbD) – A model for managing comparability risks and optimizing process development for Cell Therapy and Immunotherapy processes (Breakfast Workshop Hosted by PCT)
- Time: 7:45 AM EST
- Workshop leader: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT
Session #2: Case Study – CD34+ bone marrow stem cells: nature's blueprint for interventional cardiology
- Time: 12:40 PM EST
- Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development of NeoStem
About NeoStem, Inc.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the successful development of cellular therapies, including with respect to AMR-001 and regulatory T cells, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Media Contact Info:
- Name: Luc St-Onge, Ph.D.
- Email: firstname.lastname@example.org